Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties

12Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Prototype of monogenic disorder, sickle cell disease (SCD) is caused by a unique single mutation in the β-globin gene, leading to the production of the abnormal hemoglobin S (HbS). HbS polymerization in deoxygenated condition induces the sickling of red blood cells (RBCs), which become less deformable and more fragile, and thus prone to lysis. In addition to anemia, SCD patients may exhibit a plethora of clinical manifestations ranging from acute complications such as the frequent and debilitating painful vaso-occlusive crisis to chronic end organ damages. Several interrelated pathophysiological processes have been described, including impaired blood rheology, increased blood cell adhesion, coagulation, inflammation and enhanced oxidative stress among others. During the last two decades, it has been shown that extracellular vesicles (EVs), defined as cell-derived anucleated particles delimited by a lipid bilayer, and comprising small EVs (sEVs) and medium/large EVs (m/lEVs); are not only biomarkers but also subcellular actors in SCD pathophysiology. Plasma concentration of m/lEVs, originated mainly from RBCs and platelets (PLTs) but also from the other blood cell types, is higher in SCD patients than in healthy controls. The concentration and the density of externalized phosphatidylserine of those released from RBCs may vary according to clinical status (crisis vs. steady state) and treatment (hydroxyurea). Besides their procoagulant properties initially described, RBC-m/lEVs may promote inflammation through their effects on monocytes/macrophages and endothelial cells. Although less intensely studied, sEVs plasma concentration is increased in SCD and these EVs may cause endothelial damages. In addition, sEVs released from activated PLTs trigger PLT-neutrophil aggregation involved in lung vaso-occlusion in sickle mice. Altogether, these data clearly indicate that EVs are both biomarkers and bio-effectors in SCD, which deserve further studies.

References Powered by Scopus

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

10573Citations
N/AReaders
Get full text

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles

4871Citations
N/AReaders
Get full text

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

4236Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders

24Citations
N/AReaders
Get full text

The pathobiology of platelet and megakaryocyte extracellular vesicles: A (c)lot has changed

11Citations
N/AReaders
Get full text

Extracellular Vesicles in Sickle Cell Disease: A Promising Tool

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nader, E., Garnier, Y., Connes, P., & Romana, M. (2021, August 20). Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2021.728693

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

57%

Researcher 4

29%

Lecturer / Post doc 2

14%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 7

50%

Medicine and Dentistry 4

29%

Agricultural and Biological Sciences 2

14%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free